Celldex?s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glio

E

EGBOT

Guest
Celldex?s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

HTML:
Celldex Therapeutics, Inc. today presented positive results from the Company?s randomized, double?blind Phase 2 study of RINTEGA (rindopepimut) in patients with EGFRvIII?positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology in Chicago.

Source: Celldex?s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma
 

Create an account or login to comment

You must be a member in order to leave a comment

Create account

Create an account on our community. It's easy!

Log in

Already have an account? Log in here.

Latest threads

Back
Top